Anti-depressant for Rett syndrome

We are pleased to announce the licensing of two key pieces of intellectual property, and associated know-how, around the use of an existing glutamate modulator, for the treatment of Rett Syndrome and opiate-induced respiratory depression, to AMO Pharma. Please see here for the recent press release.